The Chemours Company

NYSE:CC Stock Report

Market Cap: US$4.0b

Chemours Future Growth

Future criteria checks 4/6

Chemours is forecast to grow earnings and revenue by 115.5% and 4.8% per annum respectively. EPS is expected to grow by 115.5% per annum. Return on equity is forecast to be 55.7% in 3 years.

Key information

115.5%

Earnings growth rate

115.47%

EPS growth rate

Chemicals earnings growth19.1%
Revenue growth rate4.8%
Future return on equity55.69%
Analyst coverage

Good

Last updated28 Apr 2026

Recent future growth updates

Recent updates

CC: Cooling Partnership And 2026 Outlook Will Support Further Earnings Upside

Analysts now cite slightly higher long term revenue growth, profit margin, and P/E assumptions as reasons for raising Chemours fair value estimate from $25.00 to $29.00 per share. What's in the News Chemours and 2CRSi entered a Joint Development Agreement following the qualification of Chemours' Opteon two phase immersion cooling fluid in current generation 2CRSi servers, aimed at advancing two phase cooling technologies for high density IT infrastructure and AI workloads (Key Developments).

CC: Share Repurchases And 2026 Outlook Will Support Earnings Upside

Analysts have raised their Chemours price target from $21.00 to $25.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Chemours completed its share repurchase program announced on May 2, 2022, buying back 10,342,722 shares (6.76%) for a total of $309.28 million, with no additional shares repurchased between October 1, 2025 and December 31, 2025 (Key Developments).

CC: PFAS Litigation Will Drive Cautious Outlook Despite Cooling Technology Partnership

Analysts have maintained their $17.00 price target for Chemours, citing updated assumptions that include a 10.25% discount rate, 3.37% revenue growth, a 13.84% profit margin, and a future P/E of 3.87x, which they state continue to support the prior fair value view. What's in the News Chemours reported that between October 1, 2025 and December 31, 2025, it repurchased 0 shares for US$0 under its existing program and indicated that it has completed the buyback of 10,342,722 shares, or 6.76%, for US$309.28 million under the authorization announced on May 2, 2022 (Key Developments).

CC: PFAS Legal Overhang And Cooling Partnership Will Shape Balanced Return Outlook

Analysts have raised their price target on Chemours from $13.00 to $17.00, citing updated assumptions around discount rate, revenue growth, profit margins, and future P/E that change their view of the company’s risk and earnings potential. What's in the News Chemours and 2CRSi entered a Joint Development Agreement after Chemours' Opteon two phase immersion cooling fluid was qualified in current generation 2CRSi servers, with a focus on advanced cooling for high density IT, AI, and next generation chips, and an emphasis on end user and environmental benefits.

Chemours: No Rush To Buy The Dip Given Non-AI Pressures (Downgrade)

Feb 23

CC: Earnings Outlook And PFAS Legal Overhang Will Shape Future Upside

Analysts have revised their Chemours price target from $18.00 to $21.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that slightly adjust the risk and earnings profile they are using in their models. What's in the News Chemours issued new Full Year 2026 earnings guidance, with management indicating an expectation for Net Sales growth in the 3% to 5% range.

CC: PFAS Class Action Risk Will Limit Future Shareholder Returns

Analysts have kept their Chemours fair value estimate steady at $13.00, with the latest price target grounded in unchanged fair value assumptions, along with updated views on discount rate, revenue growth, profit margin and future P/E levels. What's in the News On January 6, 2026, a Montana federal judge denied motions to dismiss a class action against DuPont/Chemours, 3M and several other gear and materials manufacturers related to alleged toxic PFAS chemicals in firefighter turnout gear.

The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth

Feb 03
The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth

CC: Legal Overhang And Margin Reset Will Shape Balanced Outlook

Analysts have trimmed their price target on Chemours to about US$16 from roughly US$18, pointing to adjustments in profit margin expectations and valuation multiples, even though assumptions for revenue growth and future P/E have shifted. What's in the News A Montana federal judge denied motions to dismiss a class-action lawsuit involving PFAS in firefighter turnout gear, allowing claims against DuPont/Chemours and other manufacturers to move forward, including Racketeer Influenced Corrupt Organizations (RICO) claims that will remain active pending a related Ninth Circuit decision (Lawsuits & Legal Issues).

CC: PFAS Lawsuit And Weaker Margins Will Restrain Future Shareholder Returns

Analysts have kept their Chemours fair value estimate steady at US$13.00. The latest price target update reflects adjusted assumptions around discount rate, revenue growth, profit margin and future P/E rather than a change in headline valuation.

CC: Future Profitability Challenges Will Temper Benefits Of Completed Share Buybacks

Analysts have modestly raised their price target on Chemours to 13.00 dollars, reflecting slightly stronger revenue growth expectations and higher assumed future valuation multiples, while this is partially offset by a more cautious view on long term profitability and risk. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).

CC: Long-Term Margin Outlook Will Offset Near-Term Losses And Completed Buybacks

Analysts have raised their price target on Chemours from 11 dollars and 41 cents to 13 dollars, reflecting expectations for significantly stronger long term profit margins, despite slightly more conservative assumptions for revenue growth and valuation multiples. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).

CC: Global Supply Agreements And Buybacks Will Drive Undervalued Shares Higher

Analysts have adjusted their price target for Chemours. They are maintaining the fair value estimate at $17.78, but have slightly increased the discount rate and are projecting a modest decrease in both expected revenue growth and profit margin based on recent outlook factors.

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

Analysts have raised their price target for Chemours by $1.00, reflecting updated assumptions for modestly improved fair value and profit margin forecasts. What's in the News Chemours has entered into strategic agreements with SRF Limited to strengthen its global supply chain, enhance operational flexibility, and increase capacity for key materials such as fluoropolymers and fluoroelastomers (Key Developments).

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

Analysts have raised their price target for Chemours from $15.44 to $16.78, citing improved profit margins and slight increases in projected revenue growth as key factors for the update. What's in the News Chemours signed strategic agreements with SRF Limited to strengthen its global supply chain, increase operational flexibility, and secure fluoropolymer and fluoroelastomer capacity for multiple industries (Client Announcements).

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

The modest increase in Chemours’ Consensus Analyst Price Target reflects slightly higher forward P/E expectations, while the discount rate remains stable, resulting in a revised fair value of $15.44. What's in the News Chemours signed strategic agreements with SRF Limited to enhance global supply chain, increase operational flexibility, and access capacity for fluoropolymers and fluoroelastomers, with no upfront capital investment required.

The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%

Sep 03
The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%

Is It Time To Consider Buying The Chemours Company (NYSE:CC)?

Jul 26
Is It Time To Consider Buying The Chemours Company (NYSE:CC)?

The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Jul 04
The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Chemours (NYSE:CC) Has No Shortage Of Debt

Jun 29
Chemours (NYSE:CC) Has No Shortage Of Debt

We Like The Quality Of Chemours' (NYSE:CC) Earnings

May 14
We Like The Quality Of Chemours' (NYSE:CC) Earnings

Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

Apr 25
Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

What Is The Chemours Company's (NYSE:CC) Share Price Doing?

Mar 19
What Is The Chemours Company's (NYSE:CC) Share Price Doing?

It's Down 27% But The Chemours Company (NYSE:CC) Could Be Riskier Than It Looks

Mar 04
It's Down 27% But The Chemours Company (NYSE:CC) Could Be Riskier Than It Looks

Chemours (NYSE:CC) Seems To Be Using A Lot Of Debt

Jan 24
Chemours (NYSE:CC) Seems To Be Using A Lot Of Debt

Are Investors Undervaluing The Chemours Company (NYSE:CC) By 50%?

Jan 08
Are Investors Undervaluing The Chemours Company (NYSE:CC) By 50%?

Earnings and Revenue Growth Forecasts

NYSE:CC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20286,697N/A4177457
12/31/20276,3764093206399
12/31/20266,0372382275409
12/31/20255,808-38651264N/A
9/30/20255,837-320-12265N/A
6/30/20255,850-412-54258N/A
3/31/20255,78828-797-455N/A
12/31/20245,78269-993-633N/A
9/30/20245,83563-675-289N/A
6/30/20245,814106-693-297N/A
3/31/20245,904-3299390N/A
12/31/20236,078-253186556N/A
9/30/20236,004-317-67235N/A
6/30/20236,294-87117405N/A
3/31/20236,566489337629N/A
12/31/20226,831578448755N/A
9/30/20227,031908485808N/A
6/30/20226,933881500818N/A
3/31/20226,673746460783N/A
12/31/20216,345608537814N/A
9/30/20216,108394712959N/A
6/30/20215,662256720947N/A
3/31/20215,100215581802N/A
12/31/20204,969219540807N/A
9/30/20204,984-117544854N/A
6/30/20205,140-117452843N/A
3/31/20205,455-46284738N/A
12/31/20195,526-52169650N/A
9/30/20195,637407N/A509N/A
6/30/20195,876606N/A563N/A
3/31/20196,284792N/A900N/A
12/31/20186,638995N/A1,140N/A
9/30/20186,7491,081N/A1,184N/A
6/30/20186,7051,013N/A954N/A
3/31/20186,476893N/A795N/A
12/31/20176,183746N/A640N/A
9/30/20175,930288N/A607N/A
6/30/20175,744285N/A693N/A
3/31/20175,540106N/A599N/A
12/31/20165,4007N/A594N/A
9/30/20165,438151N/A626N/A
6/30/20165,526-82N/A541N/A
3/31/20165,651-82N/A456N/A
12/31/20155,717-90N/A182N/A
9/30/20155,90675N/A372N/A
6/30/20156,052211N/A501N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.4%).

Earnings vs Market: CC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CC is expected to become profitable in the next 3 years.

Revenue vs Market: CC's revenue (4.8% per year) is forecast to grow slower than the US market (11% per year).

High Growth Revenue: CC's revenue (4.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CC's Return on Equity is forecast to be very high in 3 years time (55.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/01 19:48
End of Day Share Price 2026/05/01 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

The Chemours Company is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullAlembic Global Advisors
David ColemanArgus Research Company
Michael LeitheadBarclays